Clinical guideline on selective vitamin D testing for diagnosing and monitoring deficiency in adults and children, with laboratory recommendations relevant to Australia and New Zealand. It covers testing indications, supplementation evidence, assay limitations, interpretation of serum 25-hydroxyvitamin D (25OH-D), and retesting frequency. The guideline recommends reporting results in nmol/L, targeting levels greater than 50 nmol/L at the end of winter, and retesting no earlier than three months after starting supplementation or changing dose. Routine screening of healthy populations and high-dose annual cholecalciferol replacement are discouraged. Guideline number 1/2013 lists its latest approval as December 2023 and next review as December 2027.
Free preview text
The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
Guideline
Subject: Use and Interpretation of Vitamin D testing
Approval Date: May 2013, May 2019, December 2023
Review Date: December 2027
Review By: Chemical Pathology Advisory Committee
Number: 1/2013
__________________________________________________________________________
Introduction
The purpose of this Guideline is to clarify the role of vitamin D testing in the context of diagnosing
and monitoring vitamin D deficiency states and their treatment.
Summary of Evidence-based Recommendations
• The following describe indications for initial testing of vitamin D status for adult patients:
o Signs, symptoms and/or planned treatment of osteoporosis or osteomalacia
o Increased alkaline phosphatase with otherwise normal liver function tests
o Hyperparathyroidism, hypo- or hypercalcaemia, hypophosphataemia
o Malabsorption (e.g. cystic fibrosis, short bowel syndrome, inflammatory bowel
disease, untreated coeliac disease, bariatric surgery)
o Deeply pigmented skin, or chronic and severe lack of sun exposure for cultural,
medical, occupational or residential reasons
o Medications known to decrease 25OH-D levels (mainly anticonvulsants)
o Chronic renal failure and renal transplant recipients
• In addition, the following are indications for testing of children:
o Signs, symptoms and/or planned treatment of rickets
o Infants of mothers with established vitamin D deficiency
o Exclusively breastfed babies in combination with at least one other risk factor
o Siblings of infants or children with vitamin D deficiency
• Vitamin D should be measured as 25-hydroxyvitamin D (25OH-D) and reported in nmol/L
units.
• Clinicians should be aware that current vitamin D assay methods, may give different results
and should be aware of the limitations of the method used in the laboratory that most of their
patients attend. It is advisable to monitor serum 25OH-D levels following treatment in the
same laboratory.
• A vitamin D assay that measures only the 25OH-D3 form is sufficient for use in Australia and
New Zealand.
• The target level should be greater than 50 nmol/L at the end of winter. All laboratories should
be encouraged to report the same decision limits.
• Testing for 25OH-D should be selective and high dose annual replacement of cholecalciferol
should be discouraged.
• Serum 25OH-D levels should be retested no earlier than 3 months following commencement
of supplementation with vitamin D or change in dose.
• In individuals at risk of vitamin D deficiency, measurement of 25OH-D is an appropriate,
case-finding strategy. Routine screening of healthy infants, children and adults (including
pregnant women) for vitamin D deficiency is currently not recommended.
1. Indications for assessment of vitamin D status
1.1. Who should be tested?
Page 2
2
The quality of the evidence for the health benefits of an adequate vitamin D status is highly variable.
As the main source of vitamin D is UVB sunlight exposure, vitamin D status as assessed by the
measurement of 25 hydroxyvitamin D (25OH-D) is correlated with time spent outdoors, exercise and
other aspects of a healthy lifestyle including body weight. Vitamin D insufficiency is associated with
low levels of exercise, obesity and/or reduced sun light exposure, such as occur more commonly in
the elderly, the overweight, the frail and unwell or institutionalised and where there are occupational,
racial or cultural reasons.1,2 The recommendations below are broadly consistent with recent
guidelines on the diagnosis and management of vitamin D deficiency.3-5
Recommendation:
~In individuals at risk of vitamin D deficiency, measurement of 25OH-D is an appropriate,
case-finding strategy.
~Routine screening of adults (including pregnant women), healthy infants and children for
vitamin D deficiency is not currently recommended.
1.2. Health benefits for adults from vitamin D supplementation
Significant health benefits from vitamin D and calcium supplementation have been demonstrated in
the elderly. Randomised controlled trials (RCTs) of vitamin D plus calcium demonstrate a modest
but significant decrease in fracture risk in the elderly3,6-9 although there are insufficient data to
conclude whether vitamin D alone is effective.8.44 Supplementation of vitamin D plus calcium has
achieved an 8% reduction in risk of premature mortality in largely institutionalised frail elderly.10
Inclusion of younger, community living subjects reduces the risk to non-significant levels (P<0.08).11
RCTs demonstrate that vitamin D and calcium supplementation decrease the risk of falls in the
elderly.12 Vitamin D supplementation improves proximal muscle strength in people with moderate
vitamin D deficiency (serum 25OH-D levels <25 nmol/L).13 High dose vitamin D supplementation is
not recommended as there is evidence that annual bolus dosing of 500,000 IU vitamin D increases
the risks of falls and fractures.14
Patients with chronic kidney disease (CKD) demonstrate an association between low serum 25OH-
D levels and premature mortality.15 Current evidence is lacking to demonstrate that supplementation
reduces this risk in these patients. Guidelines for management of CKD bone mineral disorder state
that in patients with CKD stages 3-5D, measurement of 25OH-D may be appropriate, and treatment
is the same as for the general population.16
Current data do not provide consistent evidence for the benefit of vitamin D supplementation in the
treatment or prevention of other disease states including cancer, cardiovascular disease, infection,
autoimmune diseases, diabetes, multiple sclerosis or Alzheimer's disease. Two recent published
studies, the Vitamin D Assessment (ViDA) (39,40) and the Vitamin D and Omega-3 (VITAL) (41)
studies were large, long term trials conducted in 5,110 and 25,871 individuals respectively who were
treated for 5.3 and 3.3 years respectively either with monthly or daily oral cholecalciferol treatment.
Both studies showed no significant difference in cardiovascular disease, cancers rate (primary
VITAL outcome but post hoc ViDA analysis) or death. Other RCTs are underway in Europe and
Australia which should provide further evidence.17
Pregnancy
Severe maternal vitamin D deficiency has been associated with congenital rickets, and fractures in
the newborn.4 However, recent guidelines by the American College of Obstetricians and
Gynaecologists conclude that there is insufficient evidence to support screening all pregnant women
for vitamin D deficiency.5 Two published studies, the Maternal Vitamin D Osteoporosis Study
(MAVIDOS) (42) and the Maternal Vitamin D for Infant Growth (MIDG) (43) were studies conducted
in 1134 and 1164 pregnant women respectively who were randomised to daily or weekly
supplementation but both studies failed to demonstrate any beneficial effect on either whole body
bone mineral content of live born infants (MAVIDOS) or measures of foetal growth (MIDG).
Recommendations:
The following are indications for initial testing of vitamin D status for adult patients:
Page 3
3
• Signs, symptoms and/or planned treatment of osteoporosis or osteomalacia
• Increased alkaline phosphatase with otherwise normal liver function tests
• Hyperparathyroidism, hypo- or hypercalcaemia or hypophosphataemia
• Malabsorption (e.g. cystic fibrosis, short bowel syndrome, inflammatory bowel disease,
untreated coeliac disease, bariatric surgery)
• Deeply pigmented skin, or chronic and severe lack of sun exposure for cultural, medical,
occupational or residential reasons
• Medications known to decrease 25OH-D levels (mainly anticonvulsants)
• Chronic renal failure and renal transplant recipients
1.3. Paediatric patient groups
Guidelines for paediatric age groups have been published by the Australian and New Zealand Bone
and Mineral Society and Osteoporosis Australia and endorsed by the Australasian Paediatric
Endocrine Group.4 The indications described above may also be relevant for children. Additional
specific indications for testing for paediatric patients include:
• Signs, symptoms and/or planned treatment of rickets
• Infants of mothers with established vitamin D deficiency
• Exclusively breastfed babies in combination with at least one other risk factor
• Siblings of infants or children with vitamin D deficiency
2. Measurement of vitamin D
2.1. What should we measure as a marker of vitamin D status and what units should be
quoted?
Serum 25-hydroxyvitamin D (25OH-D) is the best marker for clinical assessment of an individual’s
vitamin D status. 25OH-D has a long half-life of 2-3 weeks18 and provides a measure of the vitamin
D derived from both dermal production and gut absorption from dietary or supplemental sources.19
25OH-D levels, but not levels of the active circulating metabolite, 1,25(OH)2-D, are associated with
fracture risk and falls.
Serum 1,25(OH)2-D should not be used to determine a person’s vitamin D status. Serum 1,25(OH)2-
D measurements are rarely performed in clinical practice and should be reserved for investigation of
special conditions by specialists.
The use of different units in reports is confusing for laboratory users. In Australia and New Zealand,
nmol/L is used and is recommended, but ng/mL is commonly used overseas and users should be
aware of this when referring to international guidelines.
Recommendation:
Vitamin D should be measured as 25-hydroxyvitamin D (25OH-D) and reported in nmol/L
units.
2.2. Performance of current serum 25OH-D assays
There are differences in 25OH-D levels using different vitamin D assays and despite international
efforts to standardise assays, this problem persists.
The two main types of methods available in clinical laboratories for measuring serum 25OH-D:
• Liquid chromatographic separation followed by tandem mass spectrometric detection (LC-
MS/MS)method
This method has the highest sensitivity and specificity for measurement of 25OH-D and can quantify
25OH-D2 and 25OH-D3 separately. The high cost of equipment and limited sample throughput has
constrained its widespread use in clinical laboratories. Results from different LC-MS/MS methods
can be variable and may be due to lack of standardisation in calibration and differences in sample
preparation.20,21 In addition, some LC-MS/MS methods for 25OH-D suffer from interference from C-
3 epimeric forms of 25OH-D, a metabolite of uncertain clinical significance which is present in low
Page 4
4
concentrations in adult human serum specimens,22 but more commonly seen in significant amounts
in neonatal serum.23
• Automated commercial immunoassays
Currently, most laboratories in Australia and New Zealand use automated immunoassays for routine
clinical analysis. The most commonly used automatic immunoassays in Australia for 25OH-D
measurement are from Abbott Diagnostics, DiaSorin, Roche Diagnostics and Siemens Healthcare
Diagnostics.
Results generated by current immunoassay methods for 25OH-D are highly variable24 and similar
disparity is noted between methods to that obtained prior to immunoassay modifications in 2011.25
Vitamin D Standardization Program (VDSP) performance criteria for precision and accuracy are CV
± 10% and Mean Bias ± 5% respectively. Analytical precisions also vary among different assays but
most methods can achieve a coefficient variation (CV) of less than 8% at 25OH-D levels about 40
nmol/L. Thus, changes of less than 20% in two results from the same patient over time may not be
significant.
Recommendation:
Clinicians should be aware that current vitamin D assay methods, may give different results
and should understand the limitations of the method used in the laboratory that most of their
patients attend. It is advisable to monitor serum 25OH-D levels following treatment in the
same laboratory.
2.3. Is it important to have a 25OH-D assay with equal molar cross reactivity with 25OH-D2
and 25OH-D3?
Serum 25OH-D in blood can have two isoforms: 25OH-D2 and 25OH-D3. In people not taking
ergocalciferol (vitamin D2) supplements, the concentration of serum 25OH-D2 is negligible as very
few foods contain significant amounts of vitamin D2. In Australia and New Zealand, the
measurement of 25OH-D2 is less important as almost all vitamin D supplements available are in the
form of cholecalciferol (vitamin D3).
Recommendation:
A vitamin D assay that measures only 25OH-D3 is adequate for use in Australia and New
Zealand.
3. Interpretation of results
What decision limit for 25OH-D should be quoted?
No RCT studies have been performed to help determine the ideal target level of 25OH-D.
Consequently, surrogate measures based on observational data have been used to determine
optimal levels of 25OH-D. Surrogate markers using parathyroid hormone (PTH), and fracture risk
have been largely consistent. All of the following studies support a 25OH-D decision limit of 50
nmol/L:
• An initial target threshold of 50 nmol/L was proposed using data from cholecalciferol
supplemented individuals and defined optimal levels as determined by a change in parathyroid
hormone. A pretreatment 25OH-D of less than 50 nmol/L was associated with a reduction in
PTH with cholecalciferol therapy.26
• In the placebo arm of a large intervention study where all participants received calcium and
cholecalciferol therapy, PTH changed significantly after 3 months’ treatment but only in
individuals with a pre-treatment 25OH-D below 50 nmol/L.27
• An observational study of 1200 community dwelling men over the age of 65 years showed higher
rates of hip bone loss are associated with 25OH-D values below 49 nmol/L.28
• A nested observational case-controlled study of 400 women with hip fracture matched for age
and race with 400 women without fracture showed hip fracture cases were more common in the
lowest quartile equating to a 25OH-D of less than 47.5 nmol/L.29
• A recent meta-analysis of 11 double-blind RCTs of oral vitamin D supplementation concluded
that non-vertebral fracture risk was reduced in those with a baseline 25OH-D of 43-60 nmol/L
compared with a baseline 25OH-D of less than 30 nmol/L.8
Page 5
5
Two recent statements produced by the Institute of Medicine (IOM) and a joint statement from
Australia and New Zealand Bone and Mineral Society, Endocrine Society of Australia and
Osteoporosis Australia have confirmed the target threshold of treatment is 50 nmol/L.3,30 The IOM
statement is arguably the most comprehensive assessment to date and the ANZBMS/ESA/OA
position statement has been endorsed by three major Australian societies.
A number of researchers contend that the desirable concentration of 25OH-D is equal to or greater
than 75 nmol/L.31 This higher target level for 25OH-D has been proposed based on intestinal
calcium absorption, bone mineral density change or osteoid volume with cadaveric bone biopsy
samples.32-34 All of these studies have been controversial as the data are inconsistent,
methodological differences in 25OH-D measurement are not accounted for in each study and the
relationship between each of the latter surrogate measurements and 25OH-D is non-linear.
25OH-D levels decline in winter time so seasonal effects should be considered when interpreting
measured levels.
Recommendation:
The target level should be greater than 50 nmol/L at the end of winter. Each laboratory should
be encouraged to report the same decision limits.
4. Is testing always beneficial?
There is good evidence that 25OH-D levels vary with the season and inappropriate testing and
especially testing using higher decision limits could lead to medicalisation of physiological changes
in vitamin D metabolism.
Testing of healthy individuals will reveal a significant subgroup of healthy individuals with low 25OH-
D levels. This will lead to treatment and perpetuates repeat testing without information as to whether
such patients will benefit from vitamin D supplementation.
The majority of studies of daily vitamin D replacement have demonstrated beneficial effects on
reduction in the rate of falls and, with calcium, a reduction in the rate of fractures. However, two high
dose annual dosing studies have been published with significant results demonstrating harm
(increased falls and fractures) with this type of replacement.14,35
Both high and low 25OH-D levels have been associated with higher risk of overall mortality as well
as cancer related mortality indicating a U-shaped mortality risk curve.36,37
Recommendation:
Testing for 25OH-D should be selective and high dose annual replacement of cholecalciferol
should be discouraged.
5. Frequency of retesting following commencement of vitamin D supplementation
There is general agreement that the efficacy of vitamin D supplementation should be assessed
following commencement of vitamin D supplementation3 as the concentration of serum 25OH-D
achieved on any particular regimen varies markedly amongst individuals. Such variation in serum
25OH-D arises from a variety of factors including body fat mass, decreased clearance from
interaction with dietary calcium or increased clearance due to certain disease states such as
hyperparathyroidism.38 The serum half-life of 25OH-D is of the order of 2-3 weeks.18 Based on well
described principles of pharmacokinetics, little information regarding steady-state serum levels can
be obtained from testing before 4 or 5 half-lives have passed.
Risk factors for vitamin D deficiency (age, activity levels, body weight, etc) may increase over time,
so repeat testing may be necessary, preferably at the end of winter.
Recommendation:
Serum 25OH-D levels should be retested no earlier than 3 months following commencement
of supplementation with vitamin D or change in dose. Annual assessment of 25-OHD at the
Use and Interpretation of Vitamin D testing: summary, contents and background
This guide helps you understand the scope of Use and Interpretation of Vitamin D testing before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.
Summary and overview
Use and Interpretation of Vitamin D testing is a 7-page documentcredited to Xenia L. Yarrow. Clinical guideline on selective vitamin D testing for diagnosing and monitoring deficiency in adults and children, with laboratory recommendations relevant to Australia and New Zealand. It covers testing indications, supplementation evidence, assay limitations, interpretation of serum 25-hydroxyvitamin D (25OH-D), and retesting frequency. The guideline recommends reporting results in nmol/L, targeting levels greater than 50 nmol/L at the end of winter, and retesting no earlier than three months after starting supplementation or changing dose. Routine screening of healthy populations and high-dose annual cholecalciferol replacement are discouraged. Guideline number 1/2013 lists its latest approval as December 2023 and next review as December 2027. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.
The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Clinical guideline, Vitamin D testing, Vitamin D deficiency, Chemical pathology, 25-hydroxyvitamin D, Laboratory assays, Vitamin D supplementation, Paediatrics, Australia and New Zealand with the related resources linked below.
Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.
Key topics and reader takeaways
The catalogue connects this document with Clinical guideline, Vitamin D testing, Vitamin D deficiency, Chemical pathology, 25-hydroxyvitamin D, Laboratory assays, Vitamin D supplementation, Paediatrics, Australia and New Zealand. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.
A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.
Table of contents and reading guide
The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 7 pages in the player.
Part 1
Clinical guideline
Use this section of the reading guide to identify how Clinical guideline appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 2
Vitamin D testing
Use this section of the reading guide to identify how Vitamin D testing appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 3
Vitamin D deficiency
Use this section of the reading guide to identify how Vitamin D deficiency appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 4
Chemical pathology
Use this section of the reading guide to identify how Chemical pathology appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 5
25-hydroxyvitamin D
Use this section of the reading guide to identify how 25-hydroxyvitamin D appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 6
Laboratory assays
Use this section of the reading guide to identify how Laboratory assays appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 7
Vitamin D supplementation
Use this section of the reading guide to identify how Vitamin D supplementation appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
Part 8
Paediatrics
Use this section of the reading guide to identify how Paediatrics appears in Use and Interpretation of Vitamin D testing, note important terms, and connect the subject to the wider purpose of the work.
When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.
About Xenia L. Yarrow
Doxxly credits Xenia L. Yarrow as the author or creator of Use and Interpretation of Vitamin D testing. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.
Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.
About the source organisation
The recorded source for this item is rcpa.edu.au. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.
Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.
Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.
The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.
If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.
Research questions to consider
As you read Use and Interpretation of Vitamin D testing, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.
A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.
Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.